Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercell acquires Iomai for cash and stock

Executive Summary

To strengthen its late-stage pipeline, Intercell AG (vaccines for infectious diseases) is buying Iomai (transdermal vaccines) for approximately $172mm in both cash and stock.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Transdermal
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Includes Contract
    • Payment Includes Stock
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register